Provider of audio and video products that meld the power of the Internet seamlessly with intuitive home-entertainment devices. The company's products and services are designed to enhance the entertainment experience by providing ways to access music, movies, and related content throughout the home. It possesses a portfolio of designs for new products including media servers, DVD systems, remote players and networking, and streaming devices, that are brought to market through a channel of over 800 locations throughout the United States, Canada, Europe and Mexico, and in partnership with other global consumer electronics brand. [Keywords: home entertainment*, audio*, video*, media*, internet*]
Missing: Escient's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Escient's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Escient News
Nov 28, 2022
Amber Tong Senior Editor Days after adding some finance, dealmaking and technical talent to the top team, Escient Pharma has taken the wraps off a $120 million round to go broader in the clinic. New Enterprise Associates, Abingworth and Forge Life Science Partners co-led the Series C. The San Diego biotech has been turning a new page. At the beginning of the year, co-founder Alain Baron stepped down from the CEO post, making room for Joshua Grass — who brought on a trio of new execs earlier this month: Aaron Mishel, CFO; David Houck, VP of chemistry, manufacturing & controls; and Greg Balani, director of business development. As he announced their appointments, Grass noted that Escient plans to start five more clinical trials in 2023. Escient’s specialty lies in what it calls neurosensory-inflammatory disorders, or chronic diseases that result from an excessive response to external stimuli, with symptoms ranging from itch to allergy to pain. By hitting a class of cell surface receptors known as Mas-related G-protein coupled receptors, or MRGPRs — which are expressed on sensory neurons and immune cells — the company hopes to break the vicious cycle of neuro-immune overreaction and inflammation. Specifically, the team is starting with two small molecule candidates. EP262 is an MRGPRX2 antagonist that will be tested in chronic spontaneous urticaria, chronic inducible urticaria and atopic dermatitis; EP547, an MRGPRX4 antagonist, has already completed a healthy volunteers trial and is being tested for uremic pruritus, thanks to its $77.5 million Series B two years ago. Escient hopes to start another proof-of-concept study in cholestatic pruritus. In addition to helping patients reduce the itching sensation, Grass noted that Escient is hoping its drugs can avoid “the serious side effects observed with other approaches.” Joining the syndicate for this round are Avego, PFM Health Sciences and The Eleven Fund. Existing investors include The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners, and Altitude Life Science Ventures. AUTHOR John Carroll Editor & Founder The FDA has gone out of its way several times to flatten any expectations for Spectrum’s lung cancer drug poziotinib, including slamming the regulatory door in the biotech’s face four years ago when the their executive crew came calling for a breakthrough drug designation and encouragement from the oncology wing of the FDA. That stinging early rebuke pointed straight down the path to a corrosive in-house agency review of Spectrum’s attempt to land an accelerated approval for the oral EGFR TKI and a public whipping that included a classic takedown by none other than Richard Pazdur, who slammed the company for “poor drug development” that led to confusion over the dose needed for a slice of NSCLC patients harboring HER2 exon 20 insertion mutations. Keep reading Endpoints with a free subscription Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here . As you start planning for #JPM23, we hope you will consider joining Endpoints News for our live and virtual events . For those who are celebrating Thanksgiving, we hope you are enjoying the long weekend with loved ones. And if you’re not — we’ll see you next week! Keep reading Endpoints with a free subscription Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor About 11 months after his investment firm’s blank check company helped boost EQRx’s cash coffers by about $1.3 billion, Eli Casdin is out from the biotech’s board. The day before Thanksgiving, he told EQRx’s board that he would resign at the end of that day, according to an SEC filing. The decision “was not due to any disagreement with EQRx” relating to the company’s “operations, policies or practices,” as the biotech outlined in the paperwork with the agency. Keep reading Endpoints with a free subscription Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Tyler Patchen News Reporter Toward the end of summer, Massachusetts-based CinCor Pharma was riding high with a $225 million raise, touting a positive data readout. But a closer look under the hood has revealed a few hiccups in its Phase II. CinCor on Monday unveiled topline results from its Phase II trial, dubbed HALO, evaluating baxdrostat in patients with uncontrolled hypertension who are taking up to two blood pressure medications. The trial whiffed on its primary endpoint of evaluating change from the “baseline in mean seated” systolic blood pressure (SBP) in the intent-to-treat population in all dosage levels. Read More Kyle LaHucik Associate Editor With the buzz around the Covid-19 mRNA vaccines wearing off, biotechs attempting to create the next generation of messenger RNA therapeutics are in full swing, and MIT-founded Strand Therapeutics has picked up $45 million more to do so. The Boston-based drug developer added that amount to its original $52 million Series A, disclosed in June 2021, to get its first solid tumor mRNA candidate into human trials next year. The BeiGene-partnered startup gathered the Series A1 funds from Eli Lilly, FPV, Potentum Partners, existing backer Playground Global and an “unannounced syndicate.” Keep reading Endpoints with a free subscription Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN
Escient Frequently Asked Questions (FAQ)
Where is Escient's headquarters?
Escient's headquarters is located at 6640 Intech Boulevard, Indianapolis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.